We are happy to report that the oppositions filed by our client betapharm and eight other generics manufacturers against Novartis patent EP 3 351 246 were successful; the Board of Appeal of the European Patent Office revoked the Novartis patent for lack of inventive step (file number: T0814/22-3.3.07).
In reaction to this decision, Novartis also withdrew its parallel infringement action against our client betapharm that was pending before the Düsseldorf Appeal Court.
Maiwald is a leading law firm in the field of intellectual property rights. With approximately 240 employees in Munich and Düsseldorf, Maiwald comprehensively supports companies in securing, defending and enforcing their intellectual property rights. Clients include start-ups, small and medium-sized enterprises and industrial groups in a wide range of industries. Approximately 80 patent attorneys and attorneys-at-law work internationally for clients in the fields of pharmaceuticals & biotechnology, organic chemistry & polymers, inorganic chemistry & building materials, food & agriculture, electrical engineering & mechanical engineering, communication & information technology, mobility & energy, displays & light, measuring & process engineering as well as medical technology & imaging. Maiwald advises and represents clients with regard to patents & utility models, supplementary protection certificates, trademarks & designs, copyright law, competition & antitrust law, compliance, contract law, employee invention law, pharmaceutical law, data protection and plant variety protection. The magazine Managing Intellectual Property named Maiwald “European SPC/Patent Prosecution Firm of the Year 2021”, “European Cross-Border Patent Litigation Team of the Year 2021” and “German Impact Case of the Year 2021”.